Bayer Pharmaceuticals

President Trump's executive order implementing a "Most Favored Nation" pricing policy could slash U.S. drug prices by 30-80%, sending shockwaves through the global pharmaceutical industry.

Leading experts from Bayer Pharmaceuticals and IPG Health will convene on March 5th, 2025, to discuss the transformative potential of cell and gene therapies in rare disease treatment.

Bayer has initiated clinical investigations into sepsis-associated coagulopathy (Study 22265), addressing a critical area with high mortality rates and limited treatment options.

The CDSCO's waiver of local clinical trial requirements for drugs approved in well-regulated markets aims to expedite access to essential medications for Indian patients.